DREAMM-9: Phase I Study of Belantamab Mafodotin with Standard of Care in non-transplant-eligible Patients with newly diagnosed multiple Myeloma

被引：0

作者：

Raab, M. S. ^{[1
]}

Usmani, S. Z. ^{[2
]}

Mielnik, M. ^{[3
]}

Koh, Y. ^{[4
]}

Alonso Alonso, A. ^{[5
]}

Leleu, X. ^{[6
]}

Quach, H. ^{[7
]}

Min, C-K. ^{[8
]}

Janowski, W. ^{[9
]}

Abdallah, A. -O. ^{[10
]}

Garg, M. ^{[11
]}

Sandhu, I. ^{[12
]}

San Miguel, Ocio E. M. ^{[13
]}

Oriol, A. ^{[14
,15
]}

Rodriguez-Otero, P. ^{[16
]}

Ramasamy, K. ^{[17
]}

Weisel, K. ^{[18
]}

Besemer, B. ^{[19
]}

Cavo, M. ^{[20
]}

Zhou, X. L. ^{[21
]}

Kaisermann, M. C. ^{[22
]}

Bego Marques, C. M. ^{[23
]}

Williams, D. ^{[22
]}

Carreno, F. ^{[22
]}

Kremer, B. E. ^{[22
]}

Gupta, I. V. ^{[22
]}

Hus, M. ^{[3
]}

机构：

[1] Univ Hosp Heidelberg, Dept Hematol Oncol & Rheumatol, Heidelberg, Germany

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[3] Med Univ Lublin, Dept Hematooncol & Bone Marrow Transplantat, Lublin, Poland

[4] Seoul Natl Univ Hosp, Seoul, South Korea

[5] Hosp Quiron Madrid, Madrid, Spain

[6] CHU Poitiers, Poitiers, France

[7] St Vincent Hosp Melbourne, Melbourne, Vic, Australia

[8] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea

[9] Calvary Mater Newcastle, Newcastle, NSW, Australia

[10] Univ Kansas, Kansas City, KS USA

[11] Leicester Royal Infirm, Leicester, Leics, England

[12] Univ Alberta, Edmonton, AB, Canada

[13] Univ Cantabria, Hosp Univ Marques de Valdecilla IDIVAL, Santander, Spain

[14] Hosp Univ Germans Trias & Pujol HUGTP, Inst Catala Oncol, Badalona, Spain

[15] Hosp Univ Germans Trias & Pujol HUGTP, Inst Josep Carreras, Badalona, Spain

[16] Clin Univ Navarra, Dept Hematol, Pamplona, Spain

[17] Churchill Hosp, Oxford, England

[18] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[19] Univ Tubingen, Tubingen, Germany

[20] Univ Bologna, Ist Ematol Seragnoli, IRCCS Azienda Osped Univ Bologna, Bologna, Italy

[21] GlaxoSmithKline, Waltham, MA USA

[22] GlaxoSmithKline, Upper Providence, PA USA

[23] GlaxoSmithKline, Barcelona, Spain

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 2期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P433

引用

页码：145 / 146

页数：2

共 50 条

[1] DREAMM-9: Phase I Study of Belantamab Mafodotin Plus Standard of Care in Patients with TransplantIneligible Newly Diagnosed Multiple Myeloma
Usmani, Saad Z.
Alonso, Aranzazu Alonso
Quach, Hang
Koh, Youngil
Guenther, Andreas
Min, Chang-Ki
Zhou, Xiaoou L.
Kaisermann, Morrys
Mis, Lukasz M.
Williams, Danae
Yeakey, Anne
Ferron-Brady, Geraldine
Figueroa, David J.
Kremer, Brandon E.
Gupta, Ira
Janowski, Wojciech
BLOOD, 2021, 138
[2] A phase I study of belantamab mafodotin in combination with standard of care in newly diagnosed multiple myeloma: an interim analysis of DREAMM-9
Leypoldt, L.
Usmani, S. Z.
Mielnik, M.
Byun, J. M.
Alonso, A.
Abdallah, A. -O
Garg, M.
Quach, H.
Min, C. -K
Janowski, W.
San Miguel, Ocio E. M.
Weisel, K.
Oriol, A.
Sandhu, I
Rodriguez-Otero, P.
Ramasamy, K.
Egger, J. L.
Williams, D.
Ma, J.
Kaisermann, M. C.
Hus, M.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 181 - 182
[3] A phase 1 study of belantamab mafodotin in combination with standard of care in newly diagnosed multiple myeloma: An interim analysis of DREAMM-9.
Usmani, Saad Zafar
Mielnik, Michal
Byun, Ja Min
Alonso, Aranzazu Alonso
Abdallah, Al-Ola A.
Garg, Mamta
Quach, Hang
Min, Chang-Ki
Janowski, Wojciech
Ocio, Enrique M.
Weisel, Katja
Oriol, Albert
Sandhu, Irwindeep
Rodriguez-Otero, Paula
Ramasamy, Karthik
Egger, Jacqueline L.
Williams, Danae
Ma, Jie
Kaisermann, Morrys C.
Hus, Marek
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[4] DREAMM-9: Phase III study of belantamab mafodotin plus VRd versus VRd alone in transplant-ineligible newly diagnosed multiple myeloma (TI NDMM).
Usmani, Saad Zafar
Terpos, Evangelos
Janowski, Wojt
Quach, Hang
West, Sarah
Williams, Danae
Dettman, Elisha J.
Ferron-Brady, Geraldine
Luptakova, Katarina
Gupta, Ira
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[5] 30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple Myeloma
Chacon, Aurelia
Leleu, Xavier
Bobin, Arthur
CANCERS, 2023, 15 (07)
[6] Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: part 1 results of a phase I/II study
Terpos, Evangelos
Gavriatopoulou, Maria
Ntanasis-Stathopoulos, Ioannis
Malandrakis, Panagiotis
Fotiou, Despina
Migkou, Magdalini
Theodorakakou, Foteini
Spiliopoulou, Vasiliki
Kostopoulos, Ioannis V.
Syrigou, Rodanthi-Eleni
Eleutherakis-Papaiakovou, Evangelos
Gkolfinopoulos, Stavros
Tsitsilonis, Ourania E.
Kastritis, Efstathios
Dimopoulos, Meletios A.
HAEMATOLOGICA, 2024, 109 (08) : 2594 - 2605
[7] Newly diagnosed Multiple Myeloma Daratumumab-Rd - a Standard for non-transplant Eligible Patients
不详
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (06) : 380 - 381
[8] Safety and clinical activity of belantamab mafodotin plus lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: the phase 1/2 BelaRd study
Terpos, Evangelos
Gavriatopoulou, Maria
Ntanasis-Stathopoulos, Ioannis
Malandrakis, Panagiotis
Fotiou, Despina
Migkou, Magdalini
Theodorakakou, Foteini
Spiliopoulou, Vassiliki
Syrigou, Rodanthi
Eleutherakis-Papaiakovou, Evangelos
Gkolfinopoulos, Stavros
Manousou, Kyriaki
Kastritis, Efstathios
Dimopoulos, Meletios
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S103 - S103
[9] Ocular Adverse Events in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in a Phase 1/2 Trial
Terpos, Evangelos
Ntanasis-Stathopoulos, Ioannis
Gavriatopoulou, Maria
Malandrakis, Panagiotis
Fotiou, Despina
Kanellias, Nikolaos
Migkou, Magdalini
Theodorakakou, Foteini
Spiliopoulou, Vasiliki
Syrigou, Rodanthi
Papaiakovou, Evangelos Eleutherakis
Gkolfinopoulos, Stavros
Manousou, Kyriaki
Kastritis, Efstathios
Dimopoulos, Meletios A.
BLOOD, 2022, 140 : 7267 - 7268
[10] Belantamab Mafodotin in Combination with VRd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-VRd Trial
Gonzalez-Calle, Veronica
Rey-Bua, Beatriz
Puertas, Borja
Rodriguez-Otero, Paula
de la Rubia Comos, Javier
De Arriba, Felipe
Cabanas Perianes, Valentin
Gonzalez Garcia, Maria Esther
Maria Ocio, Enrique
Encinas, Cristina
Suarez-Cabrera, Alexia
Bargay, Joan
Martinez-Lopez, Joaquin
Gonzalez-Perez, Marta
Hernandez-Rivas, Jose Angel
Rosinol, Laura
Hernandez, Miguel
Paiva, Bruno
Teresa Cedena, Maria
Puig, Noemi
Jose Lahuerta, Juan
Blade, Joan
San-Miguel, Jesus
Mateos, Maria-Victoria
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S289 - S290

← 1 2 3 4 5 →